List of Excipients in Branded Drug PEGANONE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RECORDATI RARE DISEASES INC	PEGANONE	ethotoin	55292-602	ACACIA
RECORDATI RARE DISEASES INC	PEGANONE	ethotoin	55292-602	CARBOXYMETHYLCELLULOSE SODIUM
RECORDATI RARE DISEASES INC	PEGANONE	ethotoin	55292-602	LACTOSE
RECORDATI RARE DISEASES INC	PEGANONE	ethotoin	55292-602	STEARIC ACID

PEGANONE Excipient Strategy and Commercial Opportunities for Ethotoin Tablets

Last updated: September 24, 2026

Peganone is the branded formulation of ethotoin, an older hydantoin anticonvulsant used for seizure control. Its commercial opportunity is a regulated niche product rather than a protected growth brand. The active ingredient is an established small molecule with no biosimilar pathway, limited apparent patent protection, and likely demand concentrated among patients who require continuity of therapy or cannot tolerate more commonly used anticonvulsants.

The strongest product strategy is a low-risk immediate-release tablet supported by robust supply controls, simple excipients, and a differentiated dosage form only where clinical need and FDA requirements justify the investment. A liquid, dispersible tablet, or authorized-generic strategy could create value, but each would carry formulation, stability, bioequivalence, and market-size risk.

What is Peganone and how is ethotoin regulated?

Peganone contains ethotoin, a hydantoin derivative indicated for the management of seizures. The historical U.S. product is a prescription tablet, commonly identified as a 250 mg strength. FDA labeling describes ethotoin as an anticonvulsant related pharmacologically to phenytoin but with a distinct chemical structure and clinical profile (U.S. Food and Drug Administration, n.d.-a).

Ethotoin is a small-molecule drug. It does not create a biosimilar opportunity because biosimilars apply to biological products, not conventional chemical anticonvulsants.

Attribute	Peganone / ethotoin
Active ingredient	Ethotoin
Therapeutic class	Hydantoin anticonvulsant
Historical dosage form	Immediate-release oral tablet
Common historical strength	250 mg
Regulatory pathway	Small-molecule prescription drug
Biosimilar exposure	None
Primary competitive risk	Generic or alternative-manufacturer entry
Key commercial issue	Niche demand and supply continuity
Formulation opportunity	Tablet optimization, oral liquid, dispersible or multiparticulate dosage form
Patent value	Likely limited for the legacy active ingredient and conventional tablet

Peganone should be analyzed as a legacy prescription product, not as a modern specialty drug with substantial composition-of-matter exclusivity.

What is the FDA and Orange Book status of Peganone?

Peganone has been marketed under an older FDA approval history. FDA’s Drugs@FDA and product-label records should be used to confirm the current marketing status, approved strength, holder, and any current labeling changes (U.S. Food and Drug Administration, n.d.-b).

The Orange Book is relevant for three separate questions:

1. Whether an approved Peganone or ethotoin reference product remains listed.
2. Whether the product has active patents or exclusivity codes.
3. Whether an abbreviated new drug application can rely on the product as a reference listed drug.

For a legacy product such as Peganone, commercial diligence should not assume that the brand label, reference-listed-drug status, and active commercial distribution are the same thing. FDA’s Orange Book includes discontinued-product and marketing-status information, but the applicant must verify whether the listed product remains suitable for ANDA reference purposes (U.S. Food and Drug Administration, n.d.-c).

Does Peganone have active Orange Book patents?

No significant active patent estate should be assumed for ethotoin itself or for a conventional immediate-release ethotoin tablet. The active ingredient and original product date from an earlier pharmaceutical era, making composition-of-matter patent protection highly unlikely to remain commercially relevant.

Potential residual protection could arise from:

• A later-developed formulation.
• A specific dosage regimen.
• A controlled-release product.
• A method-of-use claim.
• A manufacturing process that is separately patented.
• A trademark or trade dress right.

These rights would not automatically block a conventional generic tablet. They would need to be identified in current FDA and patent records and tested against the proposed product.

When does Peganone lose exclusivity?

Peganone’s original exclusivity period expired decades ago. The product is therefore exposed to ordinary generic competition, subject to the existence of an active reference product and the practical ability of a manufacturer to obtain an ANDA approval.

The primary commercial barriers are unlikely to be statutory exclusivity. They are more likely to include:

• Small and unstable market volume.
• Difficulty sourcing qualified ethotoin API.
• Limited commercial incentive for multiple manufacturers.
• Bioequivalence and analytical-method requirements.
• Pharmacovigilance obligations for an older anticonvulsant.
• Prescriber and patient reluctance to switch a stable seizure regimen.
• Distribution economics for a low-volume product.

Are there Paragraph IV challenges for Peganone?

A Paragraph IV challenge is relevant only if an ANDA applicant identifies an unexpired Orange Book patent and certifies that the patent is invalid, unenforceable, or will not be infringed. Given the age of ethotoin and the absence of an assumed active composition-of-matter estate, a conventional Peganone generic is more likely to proceed through a Paragraph III certification or other applicable pathway than through a meaningful Paragraph IV campaign.

No material Paragraph IV litigation should be presumed without a current patent listing and a corresponding FDA or federal court record. The commercial value of challenging a patent would also be limited if the alleged patent covered only a narrow formulation or method of use.

What excipients are appropriate for Peganone tablets?

The best initial excipient strategy is a conventional immediate-release tablet that minimizes formulation change from the established product and uses widely accepted oral solid-dose excipients.

A practical platform could include:

Formulation function	Candidate excipient classes	Commercial rationale
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Controls tablet weight and manufacturability
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Supports granule strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports compression and ejection
Film coat	Hypromellose, polyethylene glycol, titanium dioxide or approved colorants	Improves handling, identification, and swallowability

The formulation should prioritize excipient familiarity, broad supplier availability, low regulatory complexity, and reproducible dissolution. FDA’s Inactive Ingredient Database is the principal reference for assessing prior use by route, dosage form, and maximum potency exposure (U.S. Food and Drug Administration, n.d.-d).

Should lactose be used?

Lactose is a commercially practical filler if the product’s target population and labeling strategy support it. A lactose-free formulation may be preferable for differentiation, institutional purchasing, or patients with intolerance concerns. The decision should be based on dose uniformity, tablet size, stability, cost, and target-market requirements rather than on a generalized preference for or against lactose.

Should a sugar-free formulation be developed?

A sugar-free formulation would have limited value in a standard tablet unless it supports a pediatric or dysphagia-oriented dosage form. Sugar-free status is more commercially relevant for an oral liquid, chewable tablet, or orally disintegrating product.

What formulation patents could protect a new Peganone product?

A new Peganone product could pursue formulation IP, but the patent estate would likely be narrower and weaker than a conventional new chemical entity portfolio.

Potential claim areas include:

• A specific excipient ratio that improves dissolution or stability.
• A low-dust manufacturing process.
• A taste-masked oral liquid or dispersible tablet.
• A controlled-release matrix.
• A multiparticulate dosage form.
• A formulation that reduces food effect or pharmacokinetic variability.
• A moisture-protective package and tablet-coating combination.
• A pediatric dosage form with improved dose flexibility.

Patent strength would depend on unexpected technical results. A simple substitution of one conventional filler or disintegrant for another would face obviousness risk. Stronger protection would require data showing a measurable and non-predictable benefit, such as improved dissolution across pH conditions, enhanced stability, reduced degradation, or a clinically relevant pharmacokinetic advantage.

Is a liquid or pediatric Peganone product commercially attractive?

An oral liquid is the clearest differentiated dosage-form opportunity, but it also presents the highest technical risk.

Ethotoin liquid development would require evaluation of:

• Aqueous solubility and pH dependence.
• Chemical stability in the selected vehicle.
• Precipitation after dilution.
• Preservative effectiveness.
• Palatability and taste masking.
• Dose uniformity after shaking.
• Container compatibility.
• Microbial limits and in-use stability.
• Pharmacokinetic comparability with the tablet.

Candidate excipient systems could include a buffered aqueous vehicle, suspending agents, sweeteners, flavor systems, preservatives, and a wetting agent. The formulation should avoid unnecessary excipient complexity because pediatric products face tighter tolerability and acceptability expectations.

A liquid could create access value for patients who cannot swallow tablets, but the market may be too small to support a stand-alone product unless the manufacturer controls a broader anticonvulsant portfolio or secures institutional and specialty-pharmacy distribution.

What manufacturing and excipient barriers affect Peganone?

The active pharmaceutical ingredient is likely to be a more important supply constraint than the tablet excipients. Standard excipients such as microcrystalline cellulose, starch, povidone, crospovidone, and magnesium stearate are available from multiple global suppliers. Ethotoin API may have fewer qualified sources because of low demand and limited manufacturing scale.

The principal manufacturing risks are:

1. API sourcing and vendor qualification.
2. Consistent particle-size distribution.
3. Blend uniformity at low or moderate drug loading.
4. Tablet hardness versus disintegration.
5. Dissolution reproducibility.
6. Stability under heat and humidity.
7. Analytical reference-standard availability.
8. Packaging that protects the product from moisture and mechanical damage.

A dual-source API strategy would be commercially valuable. A sponsor should also retain a second-source plan for critical excipients and packaging components, even if the first launch uses a standard formulation.

What generic launch scenarios exist for Peganone?

Scenario 1: Conventional generic tablet

This is the lowest-risk entry strategy. The product would use a conventional immediate-release formulation and seek approval through the ANDA pathway, provided an acceptable reference listed drug is available.

Commercial advantages include:

• Lower development cost.
• Familiar manufacturing technology.
• Straightforward supply-chain planning.
• Limited need for clinical differentiation.

The drawback is a small addressable market and possible price erosion if multiple applicants enter.

Scenario 2: Authorized generic or brand continuation

A rights holder could preserve a premium price through an authorized-generic arrangement or a controlled distribution model. This approach may be more attractive than independent generic entry if the incumbent controls the brand, API supply, or reference product.

Scenario 3: Differentiated oral liquid

A liquid could command a higher net price and serve a defined clinical population. The opportunity depends on market size, payer treatment, and whether the product can demonstrate adequate bioequivalence or otherwise satisfy FDA requirements.

Scenario 4: Specialty low-volume supply

A manufacturer could target neurologists, specialty pharmacies, hospitals, and patients stabilized on ethotoin. The business model would rely on reliability, patient-support services, and reduced stock-out risk rather than large prescription volume.

How strong is the Peganone patent estate?

The patent estate is likely weak for the legacy tablet and stronger only if a sponsor develops a genuinely differentiated formulation.

Asset type	Likely protection level	Commercial assessment
Ethotoin composition of matter	Very low	Historical protection likely expired
Conventional immediate-release tablet	Low	Easy to design around
Tablet excipient combination	Low to moderate	Requires unexpected technical effect
Oral liquid	Moderate if novel	Depends on stability and taste-masking data
Controlled-release product	Moderate	Requires meaningful pharmacokinetic differentiation
Method of use	Low to moderate	Narrow clinical claims may remain possible
Manufacturing process	Moderate	Value depends on process specificity and enforceability
Trademark and trade dress	Potentially useful	Supports brand recognition but not molecule exclusivity

Patent strategy should focus on a family of narrow, data-supported formulation and manufacturing claims rather than broad claims to ethotoin therapy.

What litigation and settlement risks apply?

No major current litigation or settlement can be assumed for Peganone without a live patent listing, an ANDA filing, or a court docket involving the product. The relevant litigation risks would be conventional:

• Patent infringement claims against a formulation or method-of-use patent.
• Regulatory disputes over reference-product eligibility.
• ANDA suitability petitions.
• Bioequivalence disputes.
• Product-liability claims involving seizure control or abrupt substitution.
• Supply-related contract disputes.

Settlement value would probably be limited unless a later formulation patent created a meaningful market barrier. For an old anticonvulsant, the greater business risk is often commercial underinvestment rather than patent litigation.

How does Peganone compare with competing anticonvulsants?

Ethotoin competes with generic phenytoin, fosphenytoin, carbamazepine, valproate, phenobarbital, levetiracetam, and other established anticonvulsants. Newer therapies generally have stronger prescribing momentum, broader clinical positioning, or better commercial infrastructure.

Peganone’s potential advantages are continuity for existing users and a differentiated option for patients who require an alternative hydantoin-related therapy. Its disadvantages include limited market awareness, low volume, and the absence of a broad modern lifecycle program.

A sponsor should not position Peganone as a mass-market replacement for levetiracetam or other high-volume anticonvulsants. The more credible strategy is targeted continuity of supply, reliable manufacturing, and selective dosage-form innovation.

What commercial opportunities exist for Peganone?

The most credible opportunities are:

1. A dependable generic or branded-generic 250 mg tablet.
2. A dual-source API and excipient supply platform.
3. A specialty-pharmacy product for patients stabilized on ethotoin.
4. A pediatric or dysphagia-oriented oral liquid.
5. A dispersible or multiparticulate formulation.
6. A co-promotion or licensing arrangement with a company already selling anticonvulsants.
7. A portfolio acquisition involving other low-volume neurological products.

The product is unlikely to support a large standalone commercial organization. It may be attractive as an add-on asset for a company with existing manufacturing, pharmacovigilance, regulatory, and specialty-distribution infrastructure.

Key Takeaways

• Peganone is the legacy brand for ethotoin, an established small-molecule hydantoin anticonvulsant.
• The original molecule and conventional tablet are unlikely to have meaningful remaining patent exclusivity.
• No biosimilar risk exists; competition would come from generics and alternative anticonvulsants.
• A standard immediate-release tablet is the lowest-risk commercial formulation.
• Excipients should be selected for regulatory precedent, supply security, dissolution performance, and manufacturing robustness.
• An oral liquid or dispersible formulation could create differentiation but would require substantial stability, palatability, and bioequivalence work.
• The strongest business case is a niche continuity-of-supply strategy, not a high-volume branded launch.
• Formulation patents would require unexpected technical results and would likely be narrower than composition-of-matter patents.
• API sourcing and market size are likely to pose greater risks than conventional tablet excipients.
• An acquisition, licensing, or authorized-generic model may produce better returns than a stand-alone launch.

FAQs

Is Peganone still commercially available?

Availability depends on current manufacturer, distributor, and FDA marketing-status records. The product should be verified through Drugs@FDA, DailyMed, the Orange Book, and commercial wholesaler data before launch planning.

Can a company develop a generic ethotoin tablet without licensing the Peganone trademark?

Yes. A generic applicant would generally seek approval based on the applicable FDA reference-product pathway and would market the product under its own established name. The Peganone trademark would not be required for a non-branded generic.

Can excipient differences prevent approval of an ethotoin generic?

Yes. Different excipients are permissible, but the finished product must meet applicable pharmaceutical quality, dissolution, stability, labeling, and bioequivalence requirements. Excipients that affect absorption, tolerability, or product performance can create regulatory risk.

Would an orally disintegrating ethotoin tablet qualify for patent protection?

It could, but patentability would depend on novelty, nonobviousness, enablement, and evidence of a technical advantage. The dosage form alone would not guarantee strong protection.

Is Peganone a good candidate for 505(b)(2) development?

A 505(b)(2) strategy could be considered for a materially different dosage form, such as an oral liquid or controlled-release product, where reliance on published data or an approved product is appropriate. The pathway would not eliminate the need to address formulation performance, clinical bridging, and product-specific safety requirements.

References

1. U.S. Food and Drug Administration. (n.d.-a). Peganone (ethotoin) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (n.d.-d). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: United States Pharmacopeial Convention.
6. U.S. Food and Drug Administration. (n.d.-e). Electronic Orange Book patent and exclusivity information. https://www.accessdata.fda.gov/scripts/obd/